{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T02:28:23Z","timestamp":1791340103863,"version":"4.3.1"},"reference-count":44,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,12,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The 21st century ushered in the dawn of a new era of targeted therapeutics and a dramatic shift in the management of chronic-phase chronic myeloid leukemia (CP-CML) patients. Groundbreaking scientific and translational studies have led to the rapid development and approval of several effective BCR-ABL tyrosine kinase inhibitors (TKIs). In the United States, there are currently 3 approved BCR-ABL TKIs for newly diagnosed CP-CML patients. It is anticipated that clinical outcomes will continue to improve as more TKIs that address unmet medical needs are approved. However, to achieve this goal, it is critical to carefully monitor and optimally manage patients. To this end, the latest seminal clinical trial results of approved and investigational BCR-ABL TKIs and some of the salient unique features of each of these agents are summarized herein.<\/jats:p>","DOI":"10.1182\/asheducation-2011.1.121","type":"journal-article","created":{"date-parts":[[2011,12,7]],"date-time":"2011-12-07T15:33:13Z","timestamp":1323271993000},"page":"121-127","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":11,"title":["Tyrosine Kinase Inhibitor Therapy for Chronic Myeloid Leukemia: Approach to Patients with Treatment-Naive or Refractory Chronic-Phase Disease"],"prefix":"10.1182","volume":"2011","author":[{"given":"Catherine C.","family":"Smith","sequence":"first","affiliation":[{"name":"Department of Hematology\/Oncology, University of California-San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil P.","family":"Shah","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, University of California-San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111716115165000_B1","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1182\/blood-2006-02-004580","article-title":"Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations","volume":"108","author":"Bradeen","year":"2006","journal-title":"Blood"},{"key":"2019111716115165000_B2","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1200\/JCO.2007.15.8154","article-title":"Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis","volume":"26","author":"de Lavallade","year":"2008","journal-title":"J Clin Oncol"},{"key":"2019111716115165000_B3","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1182\/blood-2010-03-273979","article-title":"Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)","volume":"116","author":"Hughes","year":"2010","journal-title":"Blood"},{"key":"2019111716115165000_B4","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet","volume":"27","author":"Baccarani","year":"2009","journal-title":"J Clin Oncol"},{"key":"2019111716115165000_B5","unstructured":"NCCN Clinical Practice Guidelines in Oncology\n          Chronic Myelogenous Leukemia\n          Accessed September 19, 2011\n          Version 2.2012. http:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp#site"},{"key":"2019111716115165000_B6","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1182\/asheducation-2011.1.128","article-title":"Educational Session: Managing Chronic Myeloid Leukemia as a Chronic Disease","volume":"2011","author":"Hochhaus","year":"2011","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"2019111716115165000_B7","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1182\/blood.V114.22.1126.1126","article-title":"International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib [Abstract]","volume":"114","author":"Deininger","year":"2009","journal-title":"Blood"},{"key":"2019111716115165000_B8","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1182\/blood-2003-01-0025","article-title":"Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha","volume":"102","author":"Cortes","year":"2003","journal-title":"Blood"},{"key":"2019111716115165000_B9","doi-asserted-by":"crossref","first-page":"4754","DOI":"10.1200\/JCO.2008.20.3869","article-title":"High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses","volume":"27","author":"Cortes","year":"2009","journal-title":"J Clin Oncol"},{"key":"2019111716115165000_B10","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1182\/blood-2008-06-161737","article-title":"Impact of early dose intensity on cytogenetic and molecular responses in chronic-phase CML patients receiving 600 mg\/day of imatinib as initial therapy","volume":"112","author":"Hughes","year":"2008","journal-title":"Blood"},{"key":"2019111716115165000_B11","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1182\/blood-2003-11-3800","article-title":"High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia","volume":"103","author":"Kantarjian","year":"2004","journal-title":"Blood"},{"key":"2019111716115165000_B12","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1200\/JCO.2009.25.3724","article-title":"Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study","volume":"28","author":"Cortes","year":"2010","journal-title":"J Clin Oncol"},{"key":"2019111716115165000_B13","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1200\/JCO.2010.32.0598","article-title":"Tolerability-adapted imatinib 800 mg\/d versus 400 mg\/d versus 400 mg\/d plus interferon-alpha in newly diagnosed chronic myeloid leukemia","volume":"29","author":"Hehlmann","year":"2011","journal-title":"J Clin Oncol"},{"key":"2019111716115165000_B14","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1182\/blood.V114.22.1125.1125","article-title":"Maintaining imatinib \u2265 600 mg daily in the first 12 months of chronic phase CML treatment is associated with superior event-free survival at 5 years [Abstract]","volume":"114","author":"Osborn","year":"2009","journal-title":"Blood"},{"key":"2019111716115165000_B15","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1038\/leu.2008.225","article-title":"A population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trials","volume":"22","author":"Lucas","year":"2008","journal-title":"Leukemia"},{"key":"2019111716115165000_B16","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1182\/blood-2007-06-093617","article-title":"Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity","volume":"110","author":"White","year":"2007","journal-title":"Blood"},{"key":"2019111716115165000_B17","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1182\/blood-2005-02-0694","article-title":"hOCT 1 and resistance to imatinib","volume":"106","author":"Crossman","year":"2005","journal-title":"Blood"},{"key":"2019111716115165000_B18","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/sj.clpt.6100268","article-title":"Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia","volume":"83","author":"Wang","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"2019111716115165000_B19","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1056\/NEJMoa1004095","article-title":"Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia","volume":"363","author":"Preudhomme","year":"2010","journal-title":"N Engl J Med"},{"key":"2019111716115165000_B20","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","article-title":"Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias","volume":"354","author":"Talpaz","year":"2006","journal-title":"N Engl J Med"},{"key":"2019111716115165000_B21","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa055104","article-title":"Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL","volume":"354","author":"Kantarjian","year":"2006","journal-title":"N Engl J Med"},{"key":"2019111716115165000_B22","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1200\/JCO.2009.25.4920","article-title":"Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia","volume":"28","author":"Cortes","year":"2010","journal-title":"J Clin Oncol"},{"key":"2019111716115165000_B23","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.2009.25.4896","article-title":"Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase","volume":"28","author":"Cortes","year":"2010","journal-title":"J Clin Oncol"},{"key":"2019111716115165000_B24","doi-asserted-by":"crossref","first-page":"4933","DOI":"10.1182\/blood-2009-07-232595","article-title":"Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia","volume":"114","author":"Rosti","year":"2009","journal-title":"Blood"},{"key":"2019111716115165000_B25","doi-asserted-by":"crossref","first-page":"LBA","DOI":"10.1182\/blood.V116.21.LBA-6.LBA-6","article-title":"A randomized phase II trial of dasatinib 100 mg vs imatinib 400 mg in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): The S0325 Intergroup Trial [Abstract]","volume":"116","author":"Radich","year":"2010","journal-title":"Blood"},{"key":"2019111716115165000_B26","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N Engl J Med"},{"key":"2019111716115165000_B27","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med"},{"key":"2019111716115165000_B28","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1182\/blood.V116.21.207.207","article-title":"ENESTnd 24-month update: continued superiority of nilotinib versus imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) [Abstract]","volume":"116","author":"Hughes","year":"2010","journal-title":"Blood"},{"issue":"29","key":"2019111716115165000_B29","article-title":"Dasatinib or imatinib in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): Two-year follow-up from DASISION [abstract]","author":"Kantarjian","year":"2011","journal-title":"JCO"},{"issue":"29","key":"2019111716115165000_B30","article-title":"The incidence of BCR-ABL mutations in patients with newly diagnosed CML-CP treated with nilotinib or imatinib in ENESTnd: 24-month follow-up [abstract]","author":"Saglio","year":"2011","journal-title":"JCO"},{"issue":"21","key":"2019111716115165000_B31","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.208.208","article-title":"An ongoing phase 3 study of bosutinib (SKI-606) versus imatinib in patients with newly diagnosed chronic phase chronic myeloid leukemia [abstract]","volume":"116","author":"Gambacorti-Passerini","year":"2010","journal-title":"Blood"},{"key":"2019111716115165000_B32","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"key":"2019111716115165000_B33","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","article-title":"Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia","volume":"2","author":"Shah","year":"2002","journal-title":"Cancer Cell"},{"key":"2019111716115165000_B34","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood.V99.9.3472","article-title":"High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR\/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance","volume":"99","author":"Branford","year":"2002","journal-title":"Blood"},{"key":"2019111716115165000_B35","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0140-6736(02)07679-1","article-title":"BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study","volume":"359","author":"von Bubnoff","year":"2002","journal-title":"Lancet"},{"key":"2019111716115165000_B36","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1038\/sj.leu.2402741","article-title":"Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy","volume":"16","author":"Hochhaus","year":"2002","journal-title":"Leukemia"},{"key":"2019111716115165000_B37","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1126\/science.1099480","article-title":"Overriding imatinib resistance with a novel ABL kinase inhibitor","volume":"305","author":"Shah","year":"2004","journal-title":"Science"},{"key":"2019111716115165000_B38","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1172\/JCI30890","article-title":"Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency","volume":"117","author":"Shah","year":"2007","journal-title":"J Clin Invest"},{"key":"2019111716115165000_B39","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1182\/blood.V114.22.1122.1122","article-title":"Resistance, outcome and the development of mutations with dasatinib in patients with chronic-phase chronic myeloid leukemia (CML-CP) [Abstract]","volume":"114","author":"Shah","year":"2009","journal-title":"Blood"},{"key":"2019111716115165000_B40","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1158\/0008-5472.CAN-05-0259","article-title":"In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants","volume":"65","author":"O'Hare","year":"2005","journal-title":"Cancer Res"},{"issue":"4","key":"2019111716115165000_B41","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1182\/blood-2010-03-277152","article-title":"Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results","volume":"117","author":"Kantarjian","year":"2011","journal-title":"Blood"},{"key":"2019111716115165000_B42","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1182\/blood.V116.21.210.210","article-title":"A Phase 1 trial of oral ponatinib (AP24534) in patients with refractory chronic myelogenous leukemia (CML) and other hematologic malignancies: emerging safety and clinical response findings [Abstract]","volume":"116","author":"Cortes","year":"2010","journal-title":"Blood"},{"issue":"4","key":"2019111716115165000_B43","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.ccr.2011.03.003","article-title":"Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036","volume":"19","author":"Chan","year":"2011","journal-title":"Cancer Cell"},{"key":"2019111716115165000_B44","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1182\/blood.V114.22.644.644","article-title":"Safety and efficacy of subcutaneous-administered omacetaxine mepesuccinate in imatinib-resistant chronic myeloid leukemia (CML) patients who harbor the Bcr-Abl T315I mutation\u2013results of an ongoing multicenter phase 2\/3 study [Abstract]","volume":"114","author":"Cortes-Franco","year":"2009","journal-title":"Blood"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2011\/1\/121\/1494103\/bep00111000121.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2011\/1\/121\/1494103\/bep00111000121.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T16:12:08Z","timestamp":1574007128000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2011\/1\/121\/96955\/Tyrosine-Kinase-Inhibitor-Therapy-for-Chronic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12,10]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,12,10]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2011.1.121","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,12,10]]}}}